Why MMAD Testing Matters in Inhalation Product Development
When developing an inhaled medicine, understanding how the drug deposits in the lungs is as important as the formulation itself. One of the most widely used methods to assess this is Mass Median Aerodynamic Diameter (MMAD) testing, a way of measuring the particle size distribution within aerosols.
At Broughton, MMAD testing forms part of our comprehensive suite of inhalation testing services, enabling deeper insights into product performance and patient impact.
What is MMAD testing?
MMAD refers to the particle size at which 50% of the aerosol mass is made up of smaller particles and 50% is larger. It is a key parameter in predicting where in the respiratory tract the drug will deposit, from the mouth and throat to the deep lungs.
The ideal particle size for effective lung deposition typically falls between 1 to 5 microns, and MMAD testing helps manufacturers optimise formulation and device design to achieve this.
How is MMAD measured?
We use laser diffraction technology, such as the Malvern Spraytec, to provide real-time, high-resolution analysis of particle size distribution. This approach enables rapid data capture and supports both development and quality control stages.
Why does it matter?
For pressurised metered dose inhalers (pMDIs), dry powder inhalers (DPIs), nebulisers, and nasal sprays, MMAD testing:
• Supports regulatory submissions
• Helps demonstrate consistent dose delivery
• Reduces risk of ineffective or unsafe drug deposition
Supporting your inhalation development journey
MMAD testing complements our broader analytical services for inhalation products, from stability and emissions testing to method development and validation.
Learn more about our inhalation testing services.